Diabetes Technology & TherapeuticsPublished by Mary Ann Liebert Inc. Provides the latest developments in technology, therapeutics, and products for the diagnosis, monitoring, treatment, and prevention of diabetes. The only peer-reviewed journal that focuses on the use of new devices, drug delivery systems, and software for managing diabetes |
|
| Audience | Researchers, clinicians and C Level Executives at pharmaceutical companies and academia |
| Frequency | Monthly |
| Editorial Focus | Provides practical information for clinicians, promotes communication between developers and users of new technology and products, and covers the interface between clinical practice, industry, and government.
Diabetes Technology & Therapeutics fosters the development and use of new and emerging technologies to be applied to diabetes, including: Alternate insulin delivery methods, Continuous glucose monitoring, Artificial pancreas, Computerized case management/ telemedicine, and Detection and prevention of long-term micro- and macrovascular complications. Each issue also highlights recent developments in pharmacologic therapy and device development with original papers, accompanied by analysis commentaries, on the performance of brand-name products. |
| Editor(s) in Chief | Satish K. Garg, MD University of Colorado Denver. Barbara Davis Center for Childhood Diabetes, Aurora |
| Print Advertising Options | Adverts, Inserts & Supplements |
| Digital Advertising Options | Banners on website Banners on subscriber Table of Contents email alerts |
| Further Information | Heleen Vodégel Tel: +44 (0) 1875 825 700 hvodegel@impressmedia.com |
| Publisher | Diabetes Technology & Therapeutics is owned and published by Mary Ann Liebert, Inc. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801, USA. Phone: +1 (914) 740-2100. Fax: +1 (914) 740-2101 www.liebertpub.com |
